Virogenetics Corporation

Diagnostic Hybrids, Inc.

Health Research, Inc.

Aventis Pasteur Limited

Connaught Technology Corporation

Jill Taylor

Enzo Paoletti

James Tartaglia

Russell Robert Gettig

Michel Albert Riviere

William I Cox

Steven E Pincus

Charles De Taisne

Keith J Limbach

Marion E Perkus

Jean-Christophe Francis Audonnet

Gerard P Johnson

Elizabeth K Norton

David R Scholl

Joseph D Jollick

Laura Gillim-Ross

Louis Ross

David E Wentworth

The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.

Compositions and methods for detecting a non plus-stranded RNA virus

Recombinant viruses containing DNA coding for a rabies virus antigen, such as rabies virus G are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom are useful for eliciting an immunological against rabies virus, and, the gene products and antibodies elicited thereby are useful in assays.

Poxvirus-rabies recombinants and compositions and methods employing the recombinants

Compositions and methods for detecting severe acute respiratory syndrome coronavirus

Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid protein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.

Poxvirus&mdash;canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants

What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.

Infectious bursal disease virus recombination poxvirus vaccine

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.

Trova fowl pox virus recombinants comprising heterologous inserts

Modified recombinant vaccinia virus and expression vectors thereof

What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two measles virus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, cross-protection of dogs against canine distemper is obtained by inoculating the dog with the recombinant poxvirus.

Immunological composition of measles virus utilizing recombinant poxvirus

What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.

Marek's disease virus recombinant poxvirus vaccine

Alvac canarypox virus recombinants comprising heterlogous inserts

Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein and canine distemper virus hemagglutinin glycoprotein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus.

Poxvirus-canine distemper virus (CDV) recombinants and compositions and

Infectious bursal disease virus recombinant poxvirus vaccine

Measles virus recombinant poxvirus vaccine

Growing community of inventors

Albany, NY, United States of America

Jill Taylor